A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection

Immunological Reviews

Volumn 171, Issue , 1999, Pages 105-123

  Taylor Robinson, Andrew W ^a   Smith, Elizabeth C ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MALARIA VACCINE;

HELPER CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; MALARIA; PARASITE IMMUNITY; PATHOGENICITY; PLASMODIUM CHABAUDI; PLASMODIUM YOELII; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; BLOOD; CYTOKINES; DISEASE MODELS, ANIMAL; HOST-PARASITE RELATIONS; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM; VACCINATION; VACCINES, DNA;

EID: 0032742301     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01344.x     Document Type: Review

References (145)

1. 1. Engers HD, Godal T. Malaria vaccine development: current status. Parasitol Today 1998;14:56-64.
2. 2. Miller L, Hoffman S. Research towards vaccines against malaria. Science 1998;284:520-524.
3. 3. World Health Organization. Malaria control among refugees and displaced populations. CTD/MAL 1996;96:6-7.
4. 4. Taylor-Robinson AW. Immunoregulation of malarial infection: balancing the vices and virtues. Int J Parasitol 1998;28:135-148.
5. 5. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 1993;14:353-356.
6. 6. Marsh K. Immunology of human malaria. In: Gilles HM, Warrell DA, eds. Bruce-Chwatt's essential malariology. 3rd ed. London: Edward Arnold; 1993. p. 60-77.
7. 7. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of X irradiated sporozoites of Plasmodium berghei. Nature 1967;216:160-162.
8. 8. Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ 1979;57(Suppl 1):165-173.
9. 9. Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973;266:398-401.
10. 10. Cohen S, McGregor IA, Carrington SC. γ-globulin and acquired immunity to human malaria. Nature 1961;192:733-737.
11. 11. McGregor IA, Carrington S, Cohen S. Treatment of East African Plasmodium falciparum malaria with West African human γ-globulin. Trans R Soc Trop Med Hyg 1963;57:170-175.
12. 12. Sabchareon A, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991;45:297-308.
13. 13. Sinnis P, Nussenzweig V. Preventing sporozoite invasion of hepatocytes. In: Hoffman SL, ed. Malaria vaccine development. Washington, DC: ASM Press; 1996. p. 15-34.
14. 14. Hoffman SL, Francke ED, Hollingdale MR, Druilhe P. Attacking the infected hepatocyte. In: Hoffman SL, ed. Malaria vaccine development. Washington DC: ASM Press; 1996. p. 35-76.
15. 15. Playfair JHL, Taverne J, Bate CAW, de Souza JB. The malaria vaccine: anti-parasite or anti-disease? Immunol Today 1990;11:25-27.
16. 16. Bate CAW, Kwiatkowski D. Inhibitory immunoglobulin M antibodies to tumor necrosis factor-inducing toxins in patients with malaria. Infect Immun 1994;62:3086-3091.
17. 17. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997;27:183-189.
18. 18. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
19. 19. Mosmann TR, Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
20. 20. Allen JE, Maizels RM. Th1-Th2: reliable paradigm or dangerous dogma? Immunol Today 1997;18:387-392.
21. + T cells reactive with Plasmodium chabaudi chabaudi: distinct response kinetics for cells with Th1 and Th2 characteristics during infection. Int Immunol 1989;1:416-424.
22. + T cell clones reactive to the murine malaria parasite Plasmodium chabaudi. Immunology 1992;77:99-105.
23. + T cell lines raised against Plasmodium chabaudi show characteristics of either Th1 or Th2 cells. Parasite Immunol 1993;15:301-310.
24. 24. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of Th1 and Th2 cells in a rodent malaria infection. Science 1993;260:1931-1934.
25. 25. Stevenson MM, Tam M-F. Differential induction of helper T cell subsets during blood stage Plasmodium chabaudi AS infection in resistant and susceptible mice. Clin Exp Immunol 1993;91:77-83.
26. 26. Taylor-Robinson AW, Smith EC. Modulation of experimental blood stage malaria through blockade of the B7/CD28 T cell costimulatory pathway. Immunology 1999;96:498-504.
27. 27. Phillips RS, Mathers KE, Taylor-Robinson AW. T cells in immunity to Plasmodium chabaudi chabaudi: operation and regulation of different pathways of protection. Res Immunol 1994;145:406-412.
28. 28. Taylor-Robinson AW. Regulation of immunity to malaria: valuable lessons learned from murine models. Parasitol Today 1995;11:334-342.
29. 29. Taylor-Robinson AW, Severn A, Phillips RS. Kinetics of nitric oxide production during infection and reinfection of mice with Plasmodium chabaudi. Parasite Immunol 1996;18:425-430.
30. 30. Taylor-Robinson AW. Immunoregulation of murine malaria infections to model chronicity of parasitaemia in humans living under endemic conditions. Afr J Med Med Sci (In press).
31. 31. Cox FEG. Major animal models in malaria research: rodent. In: Wernsdorfer WH, McGregor I, eds. Malaria: principles and practice of malariology. Edinburgh: Churchill Livingstone; 1988. p. 1503-1543.
32. 32. Langhorne J. The immune response to the blood stages of Plasmodium in animal models. Immunol Lett 1994;41:99-102.
33. 33. Long CA, Daly TM, Kima P, Srivastava I. Immunity to erythrocytic stages of malarial parasites. Am J Trop Med Hyg 1994;50(Suppl):27-32.
34. 34. Taylor-Robinson AW. Are antibodies important in mice infected with Plasmodium yoelii? Parasitol Today 1993;9:96-97.
35. 35. Gilks CF, Walliker D, Newbold CI. Relationships between sequestration, antigenic variation and chronic parasitism in Plasmodium chabaudi chabaudi - a rodent malaria model. Parasite Immunol 1990;12:45-64.
36. 36. Phillips RS, Brannan LR, Balmer P, Neuville P. Antigenic variation during malaria infection - the contribution from the murine parasite Plasmodium chabaudi. Parasite Immunol 1997;19:427-434.
37. 37. Troye Blomberg M, Berzins K, Perlmann P. T-cell control of immunity to the asexual blood stages of the malarial parasite. Crit Rev Immunol 1994;14:131-155.
38. 38. Van der Hyde HC, Chang W-L, Weidanz WP. Specific immunity to malaria and the pathogenesis of disease. In: Kaufmann S, ed. Host responses to intracellular pathogens. Austin: RG Landes Company; 1997. p. 195-226.
39. 39. Stevenson MM, Lyanga JJ, Skamene E. Murine malaria: genetic control of resistance to Plasmodium chabaudi. Infect Immun 1982;38:80-88.
40. 40. Long CA. Immunity to murine malaria parasites. In: Englund PT, Sher A, eds. The biology of parasitism. New York: Alan R. Liss; 1988. p. 233-248.
41. 41. Yap GS, Stevenson MM. Plasmodium chabaudi AS: erythropoietic responses in resistant and susceptible mice. Exp Parasitol 1992;75:340-352.
42. 42. Von der Weid T, Kopf M, Köhler G, Langhorne J. The immune response to Plasmodium chabaudi malaria in interleukin-4 deficient mice. Eur J Immunol 1994;24:2285-2293.
43. 43. Linke A, Kühn R, Müller W, Honarvar N, Li C, Langhorne J. Plasmodium chabaudi chabaudi: differential susceptibility of gene-targeted mice deficient in IL-10 to an erythrocytic-stage infection. Exp Parasitol 1996;84:253-263.
44. 44. Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11:165-190.
45. 45. Burgner D, et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998;352:1193-1194.
46. 46. Stevenson MM, Tam MF, Wolf SF, Sher A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J Immunol 1995;155:2545-2556.
47. 47. Stevenson MM, Ghadirian E, Phillips NC, Rea D, Podoba JE. Role of mononuclear phagocytosis in elimination of Plasmodium chabaudi AS infection. Parasite Immunol 1989;11:529-544.
48. 48. Ockenhouse CF, Schulman S, Shear HL. Induction of crisis forms in the human malaria parasite Plasmodium falciparum by γ-interferon-activated, monocyte-derived macrophages. J Immunol 1984;133:1601-1608.
49. 49. Taylor-Robinson AW. Antimalarial activity of nitric oxide: cytostasis and cytotoxicity towards Plasmodium falciparum. Biochem Soc Trans 1997;25:262S.
50. 50. Taylor-Robinson AW, Looker M. Sensitivity of malaria parasites to nitric oxide at low oxygen tensions. Lancet 1998;351:1630.
51. 51. Taylor-Robinson AW, Smith EC. A dichotomous role for nitric oxide in protection against blood stage malaria infection. Immunol Lett 1999;67:1-9.
52. 52. Van der Hyde HC, Pepper B, Batchelder J, Cigel F, Weidanz WP. The time course of selected malarial infections in cytokine-deficient mice. Exp Parasitol 1997;85:206-213.
53. 53. Mohan K, Sam H, Stevenson MM. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 1999;67:513-519.
54. 54. White NJ. Treatment of malaria. N Engl J Med 1996;335:801-806.
55. 55. Sedegah M, Finkelman F, Hoffman SL. Interleukin 12 induction of interferon-γ-dependent protection against malaria. Proc Natl Acad Sci USA 1994;91:10700-10702.
56. 56. Hoffman SL, et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997;3:80-83.
57. 57. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-γ-dependent and -independent mechanisms. Eur J Immunol 1997;27:1958-1965.
58. 58. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-β. Immunol Today 1989;10:258-261.
59. 59. Ding A, Nathan CF, Grayear J, Derynck R, Stuehr DJ, Srimai S. Macrophage deactivating factor and transforming growth factor-β1, -β2 and -β3 inhibit induction of macrophage nitrogen oxide synthesis by interferon-γ. J Immunol 1990;145:940-944.
60. 60. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-β1. J Immunol 1995;155:1066-1073.
61. 61. Maeda H, Shiraishi A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-78.
62. 62. Omer FM, Riley EM. Transforming growth factor β production is inversely correlated with severity of murine malaria infection. J Exp Med 1998;188:39-48.
63. 63. Wenisch C, Parschalk B, Narzt E, Looareesuwan S, Graninger W. Elevated serum levels of IL-10 and IFN-γ in patients with acute Plasmodium falciparum malaria. Clin Immunol Immunopathol 1995;74:115-117.
64. 64. Wahlgren M, et al. Adhesion of Plasmodium falciparum-infected erythrocytes to human cells and secretion of cytokines (IL-1-β, IL-1Rα, IL-6, IL-8, IL-10, TGF β, TNF α, G-CSF, GM-CSF). Scand J Immunol 1995;42:626-636.
65. 65. Wenisch C, Parschalk B, Burgmann H, Looareesuwan S, Graninger W. Decreased serum levels of TGF-β in patients with acute Plasmodium falciparum malaria. J Clin Immunol 1995;15:69-73.
66. 66. Siddiqui WA, Kan SC, Kramer K, Case S, Palmer K, Niblack JF. Use of a synthetic adjuvant in effective vaccination of monkeys against malaria. Nature 1981;289:64-66.
67. 67. Lewis AP. Cloning and analysis of the gene encoding the 230-kDa merozoite surface antigen of Plasmodium yoelii. Mol Biochem Parasitol 1989;36:271-282.
68. 68. McKean PG, O'Dea KP, Brown KN. Nucleotide sequence analysis and epitope mapping of the merozoite surface protein 1 from Plasmodium chabaudi chabaudi AS. Mol Biochem Parasitol 1993;68:199-209.
69. 69. Giraldo LE, Grab DJ, Wiser MF. Molecular characterization of a Plasmodium chabaudi erythrocyte membrane-associated protein with glutamate-rich tandem repeats. J Eukaryot Microbiol 1998;45:528-534.
70. 70. Holder AA. The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 1988;41:72-97.
71. 71. Cooper JA. Merozoite surface antigen-1 of Plasmodium. Parasitol Today 9:50-54.
72. 72. Riley EM, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992;14:321-337.
73. 73. Kramer KJ, Oberst R. Antibodies to the major merozoite surface coat protein of Plasmodium falciparum (gp195) in a human population living in a malaria-endemic area of the Phillipines. Am J Trop Med Hyg 1992;47:429-439.
74. 74. Egan AF, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996;173:765-769.
75. 75. Siddiqui WA, et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci USA 1987;84:3014-3018.
76. 76. Holder AA. Preventing merozoite invasion of erythrocytes. In: Hoffman SL, ed. Malaria vaccine development. Washington, DC: ASM Press; 1996. p. 77-104.
77. 77. Daly TM, Long CA. A recombinant 15-kDa carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice. Infect Immun 1993;61:2462-2467.
78. 78. Coppel RL, et al. Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences. Nature 1984;310:789-792.
79. 79. Perlmann H, et al. Dissection of the human antibody response to the malaria antigen Pf155/RESA into epitope-specific components. Immunol Rev 1989;112:115-132.
80. 80. Kabilan L, et al. T-cell epitopes in Pf155/RESA, a major candidate for a Plasmodium falciparum malaria vaccine. Proc Natl Acad Sci USA 1988;85:5659-5663.
81. 81. Favaloro JM, et al. Structure of the RESA gene of Plasmodium falciparum. Nucleic Acids Res 1986;14:8265-8277.
82. 82. Berzins K, et al. Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci USA 1986;83:1065-1069.
83. 83. Wåhlin B, et al. Involvement of Pf155/RESA and cross-reactive antigens in Plasmodium falciparum merozoite invasion in vitro. Infect Immun 1992;60:443-449.
84. 84. Collins WE, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986;323:259-262.
85. 85. Berzins K, et al. Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect Immun 1991;59:1500-1506.
86. 86. Collins WE, et al. Immunization of owl monkeys with the ring-infected erythrocyte surface antigen of Plasmodium falciparum. Am J Trop Med Hyg 1991;44:34-41.
87. 87. Riley EM, et al. Association between immune recognition of the malaria vaccine candidate Pf155/RESA and resistance to clinical disease: a prospective study in a malaria-endemic region of West Africa. Trans R Soc Trop Med Hyg 1991;85:436-443.
88. 88. Berzins K, Perlmann P. Malaria vaccines: attacking infected erythrocytes. In: Hoffman SL, ed. Malaria vaccine development. Washington, DC: ASM Press; 1996. p. 105-143.
89. 89. Crandall I, Sherman IW. Cytoadherence-related neoantigens on Plasmodium falciparum (human malaria)-infected human erythrocytes result from the exposure of normally cryptic regions of the band 3 protein. Parasitology 1994;108:257-267.
90. 90. Baruch DI, et al. Cloning the P. falciparum gene encoding PfEMP-1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 1995;82:77-87.
91. 91. Su X-Z, et al. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 1995;82:89-100.
92. 92. McLean SA, Pearson CD, Phillips RS. Plasmodium chabaudi: evidence of antigenic variation during recrudescent parasitaemias in mice. Exp Parasitol 1982;54:296-302.
93. 93. Mota MM, Patnaik P, Jarra W, Holder AA. Antigenic variation in malaria: do we have an in vivo model? In: Proceedings of the BSP 10th Malaria Meeting, British Society for Parasitology, Edinburgh, 1998 [Abstract no. 2.8].
94. 94. Morein B, et al. Immunostimulating complexes. Clinical potential in vaccine development. Clin Immunother 1995;3:461-475.
95. 95. Mastico RA, Talbot SJ, Stockley PG. Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J Gen Virol 1993;74:541-548.
96. 96. Sidney J, et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996;45:79-93.
97. 97. Falk K, Rötzschke O, Stevanović S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
98. 98. Connelly M, et al. T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun 1997;65:5082-5087.
99. 99. Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine (In press).
100. 100. Dougan G, Hormaeche CE, Maskell DJ. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system. Parasite Immunol 1987;9:151-160.
101. + T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993;90:5214-5218.
102. 102. Tine JA, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996;64:3833-3844.
103. 103. Ockenhouse CF, et al. Phase I/IIa safety, immunogenicity and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-1673.
104. 104. Sadoff JC, et al. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria. Science 1988;240:336-338.
105. 105. Flynn JL, Weiss WR, Norris KA, Seifert HS, Kumar S, So M. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol 1990;4:2111-2118.
106. 106. González C, et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 1994;169:927-931.
107. 107. Schorr J, Knapp B, Hundt E, Kupper HA, Amann E. Surface expression of malarial antigens in Salmonella typhimurium: induction of serum antibody response upon oral vaccination of mice. Vaccine 1991;9:675-681.
108. 108. Haddad D, et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol 1995;12:175-185.
109. 109. Chatfield SN, Roberts M, Dougan G, Hormaeche C, Khan CM. The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella. Parasitology 1995;110 (Suppl):S17-S24.
110. 110. Heal KG, Taylor-Robinson AW, McConkey G, Hormaeche CE, Khan CMA, Hollingdale MR. Immunogenicity of Plasmodium falciparum liver stage antigen-1 peptides expressed as tetanus toxin fragment C fusion proteins in attenuated Salmonella typhimurium. Immunology 1998;95 (Suppl 1):106.
111. 111. Ulmer JB, Sadoff JC, Liu MA. DNA vaccines. Curr Opin Immunol 1996;8:531-536.
112. 112. Schorr J, Moritz P, Schleef M. Plasmid DNA preparation. Production of plasmid DNA in industrial quantities according to cGMP guidelines. In: Lowrie DB, ed. DNA vaccines. Methods in molecular medicine. Totowa: Humana Press; 1997. p. 1-18.
113. 113. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482.
114. 114. Darji A, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91:765-775.
115. 115. Lowrie DB. DNA vaccination exploits normal biology. Nat Med 1998;4:147-148.
116. 116. Fu TM, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-371.
117. 117. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158:2278-2284.
118. 118. Raz E, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93:5141-5145.
119. 119. Roman M, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854.
120. 120. Hengge UR, Chan EF, Foster RA, Walker PS, Vogel JC. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat Genet 1995;10:161-166.
121. 121. Xiang Z, Ertl H. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2:129-135.
122. 122. Lewis PJ, Cox GJM, van Drunen Littel-van den Hurk SD, Babiuk LA. Polynucleotide vaccines in animals: enhancing and modulating responses. Vaccine 1997;15:861-864.
123. 123. Haddad D, Liljeqvist S, Ståhl S, Perlmann P, Berzins K, Ahlborg N. Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence. Immunol Leu 1998;61:201-204.
124. 124. Barry M, Johnston SA. Biological features of genetic immunization. Vaccine 1997;15:788-791.
125. 125. Taylor-Robinson AW, Phillips RS. Infective dose modulates the balance between Th1-and Th2-regulated immune responses during blood stage malaria infection. Scand J Immunol 1998;48:527-534.
126. d-restricted epitopes. Int Immunol 1997;9:1203-1212.
127. 127. Haddad D, et al. Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. FEMS Immunol Med Microbiol 1997;18:193-202.
128. 128. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995;92:5307-5311.
129. 129. Davis HL, Brazolot Millan CL, Watkins SC. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. GeneTher 1997;4:181-188.
130. b mice. J Immunol 1996;156:3687-3695.
131. 131. Cardoso AI, Blixenkrone-Moller M, Fayolle J, Liu M, Buckland RA, Wild TF. Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity. Virology 1996;225:293-299.
132. 132. Hoffman SL, et al. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine 1997;15:842-845.
133. 133. Weiss WR, et al. A plasmid encoding murine granulocyte-macrophage colony stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998;161:2325-2332.
134. 134. Hedstrom RC, et al. The development of a multivalent DNA vaccine for malaria. Springer Semin Immunopathol 1997;19:147-159.
135. 135. Good M. Towards the development of the ideal malaria vaccine. A decade of progress in a difficult field. Med J Aust 1991;154:284-289.
136. 136. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-9870.
137. + T cell-, interferon γ-, and nitric oxide-dependent immunity. J Exp Med 1996;183:1739-1746.
138. 138. Charoenvit Y, et al. Plasmodium yoelii: 17 kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol 1995;80:419-429.
139. 139. Wang R, et al. Simultaneous induction of multiple antigen-specifc cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 1998;66:4193-4202.
140. 140. Wang R, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
141. 141. Taylor-Robinson AW. Malarial vaccine? Trends Microbiol 1999;7:15.
142. 142. Chow YH, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998;160:1320-1329.
143. 143. Barouch DH, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998;161:1875-1882.
144. 144. Wynn TA, Eltoum I, Cheever AW, Lewis FA, Gause WC, Sher A. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J Immunol 1993;151:1430-1440.
145. 145. Taylor-Robinson AW, Phillips RS. B cells are required for the switch from Th1-to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection. Infect Immun 1994;62:2490-2498.